As per the terms of the agreement, Sanofi expects to offer around 80,000 chemical compounds to Carl Nathan’s laboratory at Weill Cornellto where they will screen the compounds so as to evaluate their ability for inhibiting growth of Mycobacterium tuberculosis.
Following the screening procedure, both the companies will check whether any of the compounds need further development.
Sanofi Global R&D president Elias Zerhouni said this research collaboration with Weill Cornell will enable them to explore the potential of their existing compound library and pool the extensive knowledge of Nathan and his colleagues with Sanofi’s drug development expertise to benefit TB patients worldwide in continuation of their commitment to global health.